Integrum Valuation
Is INTEG B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of INTEG B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate INTEG B's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate INTEG B's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INTEG B?
Key metric: As INTEG B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is INTEG B's PS Ratio? | |
|---|---|
| PS Ratio | 4x |
| Sales | SEK 109.51m |
| Market Cap | SEK 440.31m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.7x |
| Enterprise Value/EBITDA | -99.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does INTEG B's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 19.3x | ||
BRAIN BrainCool | 9.8x | n/a | SEK 399.9m |
ORT B Ortoma | 6.6x | 46.2% | SEK 419.0m |
ACARIX Acarix | 58.8x | 109.8% | SEK 334.0m |
CRAD B C-Rad | 2x | 14.8% | SEK 948.6m |
INTEG B Integrum | 4x | 29.7% | SEK 440.3m |
Price-To-Sales vs Peers: INTEG B is good value based on its Price-To-Sales Ratio (4x) compared to the peer average (19.3x).
Price to Sales Ratio vs Industry
How does INTEG B's PS Ratio compare vs other companies in the SE Medical Equipment Industry?
Price-To-Sales vs Industry: INTEG B is good value based on its Price-To-Sales Ratio (4x) compared to the Swedish Medical Equipment industry average (4.7x).
Price to Sales Ratio vs Fair Ratio
What is INTEG B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4x |
| Fair PS Ratio | 7.7x |
Price-To-Sales vs Fair Ratio: INTEG B is good value based on its Price-To-Sales Ratio (4x) compared to the estimated Fair Price-To-Sales Ratio (7.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 22.70 | SEK 62.50 +175.3% | 15.2% | SEK 72.00 | SEK 53.00 | n/a | 2 |
| Nov ’25 | SEK 25.50 | SEK 62.50 +145.1% | 15.2% | SEK 72.00 | SEK 53.00 | n/a | 2 |
| Oct ’25 | SEK 26.40 | SEK 62.50 +136.7% | 15.2% | SEK 72.00 | SEK 53.00 | n/a | 2 |
| Sep ’25 | SEK 31.60 | SEK 62.50 +97.8% | 15.2% | SEK 72.00 | SEK 53.00 | n/a | 2 |
| Aug ’25 | SEK 50.40 | SEK 76.75 +52.3% | 2.9% | SEK 79.00 | SEK 74.50 | n/a | 2 |
| Jul ’25 | SEK 57.40 | SEK 76.75 +33.7% | 2.9% | SEK 79.00 | SEK 74.50 | n/a | 2 |
| Jun ’25 | SEK 50.80 | SEK 70.75 +39.3% | 5.3% | SEK 74.50 | SEK 67.00 | n/a | 2 |
| May ’25 | SEK 57.20 | SEK 70.75 +23.7% | 5.3% | SEK 74.50 | SEK 67.00 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Arcoma
SEK 146.4m
Develops, produces, and provides radiology solutions worldwide.
ARCOMA
SEK 11.10
7D
2.8%
1Y
49.0%
Mentice
SEK 560.0m
Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.
MNTC
SEK 21.90
7D
2.8%
1Y
-46.6%
Dignitana
SEK 95.8m
A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.
DIGN
SEK 1.19
7D
3.5%
1Y
-45.9%